Prothena Corporation plc (FRA:0PT)

Germany flag Germany · Delayed Price · Currency is EUR
9.45
+0.05 (0.53%)
Last updated: Dec 5, 2025, 8:04 AM CET
-31.52%
Market Cap 512.23M
Revenue (ttm) 10.05M
Net Income (ttm) -239.04M
Shares Out n/a
EPS (ttm) -4.44
PE Ratio n/a
Forward PE 67.24
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 41
Open 9.45
Previous Close 9.40
Day's Range 9.45 - 9.45
52-Week Range 3.86 - 15.20
Beta n/a
RSI 61.35
Earnings Date Feb 19, 2026

About Prothena Corporation

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potent... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 163
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0PT
Full Company Profile

Financial Performance

In 2024, Prothena Corporation's revenue was $135.16 million, an increase of 47.92% compared to the previous year's $91.37 million. Losses were -$122.31 million, -16.81% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.